City page
Lausanne biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Therapeutics (2) and Tools (1). Most visible records: AB2 Bio Ltd., SUN bioscience SA, and Debiopharm.
Which standards and public evidence are already visible?
GLP (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Lausanne.
By category
Lausanne by category
Jump into a category page filtered to this country only.
Full list
Lausanne biotech and pharma directory
3 city records currently match the active filter.
Current review cycle
AB2 Bio Ltd.
LausanneSwitzerlandTherapeutics
EPFL Innovation Park (Lausanne) Phase 3 clinical-stage autoinflammatory disease biotech developing Tadekinig alfa for IL-18 driven rare diseases, with a 650 million USD partnership with Nippon Shinyaku for US commercialization.
- Lead
- Djordje FilipovicChief Executive Officer
- Scale
- Phase 3 clinical biologics development
Current review cycle
SUN bioscience SA
LausanneSwitzerlandTools
EPFL spin-off developing the Gri3D microwell array technology for reproducible organoid generation, marketed to pharma, diagnostics, and translational research customers from the EPFL Innovation Park in Lausanne.
- Lead
- Sylke HoehnelChief Executive Officer and Co-Founder
- Scale
- Research-tools and diagnostic service delivery
Current review cycle
Debiopharm
LausanneSwitzerlandTherapeutics
Lausanne oncology and specialty-therapeutics development anchor operating with a clinical-development and partnering model.
- Lead
- Frédéric LévyChief Executive Officer, Debiopharm International
- Scale
- Clinical and partnered development
Related briefs
Briefs that mention Lausanne
Swiss Biotech & Pharma Landscape 2026: Basel, Lausanne, Zurich
A practical map of the Swiss biotech and pharma landscape in 2026 — 36 operators anchored by Roche and Novartis in Basel, peptide and oligonucleotide API at Bachem, large-scale biologics at Lonza, and Lemanic + Zurich innovation clusters.
Open briefEuropean Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK
Where to run European drug discovery services in 2026 — Evotec, Selvita, Charles River Finland, Gubra, Admescope, plus a Swiss + Polish + Nordic tool + platform layer for medicinal chemistry, DMPK, ADMET, and translational research.
Open briefEuropean AI Drug Discovery & Computational Biology 2026: Generative Design, AI Pathology, Computational Chemistry
A practical map of the European AI-enabled drug discovery and computational biology sector in 2026 — generative protein design, AI pathology, computational drug discovery CROs, AI imaging diagnostics, and the operators wiring machine learning into therapeutic pipelines.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.